Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Soleno Therapeutics ( (SLNO) ) has shared an update.
On January 21, 2025, Soleno Therapeutics’ Board of Directors approved increases to the base salaries for fiscal year 2025 and the payment of cash bonuses for fiscal year 2024 for its named executive officers, along with certain equity awards. This decision reflects the company’s ongoing efforts to enhance its executive compensation structure, which may impact its strategic operations and stakeholder expectations.
More about Soleno Therapeutics
Soleno Therapeutics operates in the biotechnology industry, focusing on developing and commercializing products for the treatment of rare diseases and disorders.
YTD Price Performance: 5.64%
Average Trading Volume: 596,012
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.08B
For detailed information about SLNO stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “…Tied to the Effort From the Administration” Boeing Stock (NYSE:BA) Blasts Up as Boeing Counts on New Top Sales Rep in China: President Trump
- “We Do Not Have Conflicting Interests….” Microsoft Stock (NASDAQ:MSFT) Gains on New Plan to be the Agentic AI Internet’s Backbone
- Battery Business Suddenly Goes South, Tesla Stock (NASDAQ:TSLA) Notches Up